Go Pro
→ Why I'm sending this one to my own family (From Behind the Markets) (Ad)tc pixel Free CVAC Stock Alerts

CureVac (CVAC) Competitors

CureVac logo
$4.66 0.00 (0.00%)
As of 08/13/2026
Compare

CVAC vs. PBLS, TNGX, VKTX, DNLI, and RLAY

Should you buy CureVac stock or one of its competitors? CureVac's main competitors and comparable companies include Parabilis Medicines (PBLS), Tango Therapeutics (TNGX), Viking Therapeutics (VKTX), Denali Therapeutics (DNLI), and Relay Therapeutics (RLAY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CureVac compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and CureVac (NASDAQ:CVAC) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

17.3% of CureVac shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Parabilis Medicines had 7 more articles in the media than CureVac. MarketBeat recorded 7 mentions for Parabilis Medicines and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 beat Parabilis Medicines' score of -0.15 indicating that CureVac is being referred to more favorably in the news media.

Company Overall Sentiment
Parabilis Medicines Neutral
CureVac Neutral

Parabilis Medicines currently has a consensus target price of $41.67, indicating a potential upside of 12.40%. Given Parabilis Medicines' stronger consensus rating and higher probable upside, equities research analysts plainly believe Parabilis Medicines is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Parabilis Medicines
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00
CureVac
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CureVac has higher revenue and earnings than Parabilis Medicines.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Parabilis MedicinesN/AN/AN/AN/AN/A
CureVac$70.74M14.78$175.50M$0.726.47

CureVac has a net margin of 199.92% compared to Parabilis Medicines' net margin of 0.00%. Parabilis Medicines' return on equity of 0.00% beat CureVac's return on equity.

Company Net Margins Return on Equity Return on Assets
Parabilis MedicinesN/A N/A N/A
CureVac 199.92%-23.03%-19.09%

Summary

Parabilis Medicines beats CureVac on 7 of the 12 factors compared between the two stocks.

How does CureVac compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and CureVac (NASDAQ:CVAC) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to Tango Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Tango Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tango TherapeuticsN/A -25.75% -23.36%
CureVac 199.92%-23.03%-19.09%

CureVac has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tango Therapeutics$62.38M69.20-$101.59M-$0.85N/A
CureVac$70.74M14.78$175.50M$0.726.47

In the previous week, Tango Therapeutics had 11 more articles in the media than CureVac. MarketBeat recorded 11 mentions for Tango Therapeutics and 0 mentions for CureVac. Tango Therapeutics' average media sentiment score of 0.38 beat CureVac's score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Tango Therapeutics Neutral
CureVac Neutral

Tango Therapeutics currently has a consensus price target of $43.31, indicating a potential upside of 69.17%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Tango Therapeutics is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tango Therapeutics
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.75
CureVac
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Tango Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Summary

Tango Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks.

How does CureVac compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and CureVac (NASDAQ:CVAC) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

CureVac has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A-$359.64M-$4.66N/A
CureVac$70.74M14.78$175.50M$0.726.47

In the previous week, Viking Therapeutics had 9 more articles in the media than CureVac. MarketBeat recorded 9 mentions for Viking Therapeutics and 0 mentions for CureVac. Viking Therapeutics' average media sentiment score of 0.55 beat CureVac's score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Viking Therapeutics Positive
CureVac Neutral

Viking Therapeutics currently has a consensus price target of $96.63, suggesting a potential upside of 191.13%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics
2 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.67
CureVac
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CureVac has a net margin of 199.92% compared to Viking Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Viking Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viking TherapeuticsN/A -94.56% -82.75%
CureVac 199.92%-23.03%-19.09%

Viking Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Summary

Viking Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks.

How does CureVac compare to Denali Therapeutics?

CureVac (NASDAQ:CVAC) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

In the previous week, Denali Therapeutics had 24 more articles in the media than CureVac. MarketBeat recorded 24 mentions for Denali Therapeutics and 0 mentions for CureVac. Denali Therapeutics' average media sentiment score of 0.72 beat CureVac's score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
CureVac Neutral
Denali Therapeutics Positive

CureVac has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVac$70.74M14.78$175.50M$0.726.47
Denali Therapeutics$330.53M11.80-$512.54M-$2.84N/A

Denali Therapeutics has a consensus target price of $35.92, indicating a potential upside of 47.20%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Denali Therapeutics
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.75

17.3% of CureVac shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

CureVac has a net margin of 199.92% compared to Denali Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Denali Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CureVac199.92% -23.03% -19.09%
Denali Therapeutics N/A -55.27%-44.24%

Summary

CureVac and Denali Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does CureVac compare to Relay Therapeutics?

CureVac (NASDAQ:CVAC) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

Relay Therapeutics has a consensus price target of $25.83, indicating a potential upside of 30.08%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CureVac
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Relay Therapeutics
2 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.86

In the previous week, Relay Therapeutics had 11 more articles in the media than CureVac. MarketBeat recorded 11 mentions for Relay Therapeutics and 0 mentions for CureVac. Relay Therapeutics' average media sentiment score of 0.95 beat CureVac's score of 0.00 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
CureVac Neutral
Relay Therapeutics Positive

17.3% of CureVac shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CureVac has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVac$70.74M14.78$175.50M$0.726.47
Relay Therapeutics$15.35M283.53-$276.48M-$1.57N/A

CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

CureVac has a net margin of 199.92% compared to Relay Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Relay Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CureVac199.92% -23.03% -19.09%
Relay Therapeutics N/A -42.27%-38.67%

Summary

Relay Therapeutics beats CureVac on 9 of the 17 factors compared between the two stocks.

Get CureVac News Delivered to You Automatically

Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CVAC vs. The Competition

Export
MetricCureVacBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.05B$3.74B$7.06B$13.10B
Dividend YieldN/A3.69%2.57%10.45%
P/E Ratio6.4710.67269.0625.28
Price / Sales14.781,262.99592.5787.62
Price / Cash4.73102.8870.4850.90
Price / Book1.3916.7812.916.24
Net Income$175.50M-$13.32M$3.45B$347.60M
7 Day PerformanceN/A1.74%1.12%1.07%
1 Month PerformanceN/A1.60%1.79%1.03%
1 Year Performance-15.43%56.43%67.69%20.77%

CureVac Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CVAC
CureVac
N/A$4.66
flat		N/AN/A$1.05B$70.74M6.47880
PBLS
Parabilis Medicines
2.0389 of 5 stars		$35.09
+3.3%		$41.67
+18.7%		N/A$4.15BN/AN/AN/A
TNGX
Tango Therapeutics
2.4076 of 5 stars		$28.61
+5.1%		$42.15
+47.4%		+272.8%$4.14B$62.38MN/A90
VKTX
Viking Therapeutics
2.9043 of 5 stars		$33.23
+1.9%		$97.88
+194.5%		-20.2%$3.88BN/AN/A20
DNLI
Denali Therapeutics
2.7094 of 5 stars		$24.05
+3.9%		$35.17
+46.2%		+67.6%$3.82B$330.53MN/A430

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CVAC) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
AI insiders stockpile guns, gold & gas masks
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why I'm sending this one to my own family
Behind the Markets editor Kelly Maguire says she has never sent an email quite like this one. A sealed congres...
Behind the Markets | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel